Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

  • End date
    Dec 23, 2024
  • participants needed
  • sponsor
Updated on 23 March 2022
ct scan
measurable disease
squamous cell carcinoma
kidney function tests
head and neck carcinoma


The study will consist of two parts :

In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-patient dose escalation.

In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of patients with recurrent or metastatic HPV-16 positive advanced malignancies.

In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies.

In both phases, tumor response will be evaluated on local assessment using RECIST 1.1.

All patients will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.

Condition HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
Treatment Avelumab, TG4001
Clinical Study IdentifierNCT03260023
Last Modified on23 March 2022


Yes No Not Sure

Inclusion Criteria

Female or male patients, aged at least 18 years (no upper limit of age)
ECOG PS 0 or 1
Life expectancy of at least 3 months
Patients with histologically or cytologically documented metastatic or refractory/recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal
Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression
Prior therapy
Availability of tumor tissue from biopsy
No more than one prior systemic treatment for recurrent /metastatic disease
At least one measurable lesion by CT scan according to RECIST 1.1
Prior treatment for recurrent or metastatic disease is not required for
Patients with recurrence/progression within 6 months after completion of prior multimodal therapy for localized or locally advanced disease
Adequate hematological, hepatic and renal function
Negative blood pregnancy test at screening for women of childbearing potential
Patients who are unsuitable for platinum-based therapy
Highly effective contraception for both male and female patients if the risk of conception exists during the study period and for 3 months after the last study treatment administration
Patients who refuse chemotherapy or other standard therapies for the treatment of metastatic or recurrent disease
Limited hepatic disease for patients with liver metastases at baseline

Exclusion Criteria

Prior exposure to cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)
Patients with CNS metastases except those with brain metastases treated locally and clinically stable during 4 weeks prior to start of study treatment, and those without ongoing neurological symptoms that are related to the brain localization of the disease
Other active malignancy requiring concurrent systemic intervention
Patients with previous malignancies other than the target malignancy to be investigated in this trial (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
Patient with any organ transplantation, including allogeneic stem cell transplantation
Patients under chronic treatment with systemic corticosteroids or other immunosuppressive drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with the exception of patients with adrenal insufficiency who may continue corticosteroids at physiological replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal systemic effect (topical, inhalation) are allowed
Any known allergy or reaction to eggs, gentamycin or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products
Any known allergy or reaction to any component of anti-PD-L1/PD-1 or its excipients
Patients with active, known, or suspected auto-immune disease or immunodeficiency, except type I diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment
History of uncontrolled intercurrent illness including but not limited to
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC), any history of anaphylaxis, or uncontrolled asthma
Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mmHg or lower)
Patients with known history or any evidence of active interstitial lung disease / pneumonitis
Clinically significant (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction (< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication/active intervention, history of myocarditis
Uncontrolled diabetes (e.g., hemoglobin A1c ≥ 8%)
Uncontrolled infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note